Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC By Ogkologos - June 25, 2025 626 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gedatolisib with Fulvestrant, With or Without Palbociclib, for HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer Potential Role of an Activated Tumour Immune Microenvironment in Predicting Benefit from Atezolizumab for TNBC Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in Patients with Stage II, IIIA, or IIIB (N2) NSCLC MOST POPULAR Researchers Create Modified Antibodies to Target RAS and p53 in Cancer April 2, 2021 Reflections from our chief clinician: The essential role of our research... February 4, 2022 Risk Tool Predicts Severe Chemotherapy Toxicity in Elderly Patients with Early... January 21, 2021 pCR Associated with Improved Survival Outcomes in Patients with Soft Tissue... April 3, 2023 Load more HOT NEWS 2020 National Cancer Opinion Survey: Cancer Screening and Mental Health During... EMA Recommends Extension of Indications for Cabozantinib The award-winning researcher behind next generation sequencing Apalutamide Plus ADT Demonstrates a Rapid, Deep, and Durable PSA Decline...
